It takes into account personal and genetic risk, including mutations such as BRCA1/2, ATM, CDH1, CHEK2, PALB2, PTEN, STK11 and TP52, as well as a polygenic risk score from 96 lower-risk common genetic variants (SNPs) with known association with breast cancer, and an updated polygenic risk model, including ethnicity- and race-specific SNPs that are shown to confer risk, to calculate a personalised risk score. This evidence concerns the gene STK11 and breast carcinoma.